Taking Aim at Pancreatic Tumors with Immunopeptidomics
Pancreatic cancer is deadly; only about 10% of patents live over five years after they are diagnosed. Patients are typically treated with several options,
Summary
Pancreatic cancer is a devastating disease with a very low five-year survival rate of only 10%. Treatment usually involves a combination of methods tailored to the patient’s specific situation. Due to the complexity and aggressive nature of the cancer, these treatments aim to manage the disease and improve quality of life, but long-term survival remains a significant challenge.
Read more…
This post is part of “Science/Immunology News”, Follow for more…!!!